木瓜直播

Though only one approved agent has been available for decades, the armamentarium has expanded

A major reason for the increase in prevalence is increased survival from improved management

While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group

"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy

A newly approved drug blocks two cytokines

Delayed diagnosis may affect patients in multiple ways

Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets

Momentum grows for earlier intervention, including pre-fibrotic disease

The approval of lazertinib/amivantamab gives clinicians one more option

TKIs are the first-line of defense, but "the more options we have the better," expert says

Got COVID from a sick family member? Maybe not, studies show

Use of immune checkpoint inhibitors comes with a variety of potential side effects

Is the risk overlooked in infants and children?

We may never have answers to some questions, expert says